Research To Practice | Oncology Videos

Featuring a slide presentation and related discussion from Dr Amrita Krishnan, including the following topics: Key efficacy and safety data with belantamab mafodotin for multiple myeloma (MM) (0:00) Guidelines for the prevention and management of keratopathy in patients receiving belantamab mafodotin (3:46) Belantamab mafodotin in combination with pomalidomide; recent data and ongoing trials with BCMA-targeted bispecific antibodies (7:30) BCMA-targeted CAR (chimeric antigen receptor) T-cell therapies under evaluation for MM (17:07) CME information and select publications

Featuring an interview with Dr Amrita Krishnan, including the following topics: Case: A woman in her early 60s who presents with renal failure and receives CyBorD for multiple myeloma (MM) (0:00) Dyspnea associated with carfilzomib; ocular toxicity with belantamab mafodotin (6:26) Efficacy, tolerability and sequencing of belantamab mafodotin for MM; myths and misperceptions (10:33) Case: A man in his early 70s who presents with back pain and compression fractures; efficacy of bispecific antibodies compared to chimeric antigen receptor (CAR) T-cell therapy (17:40) Emerging data with the GPRC5D-targeted bispecific antibody talquetamab; similarities and differences in the pharmacology of BCMA-targeted bispecific antibodies for MM (25:31) Case: A man in his mid 50s who presents with severe back pain and an L5 mass (30:22) Diagnosis and management of cytokine release syndrome, neurotoxicity and infectious complications with CAR T-cell therapy (35:05) Future roles of bispecific antibodies, CAR T-cell therapy and transplantation in the treatment of MM; eligibility criteria for patients to receive CAR T-cell therapy (44:06) CME information and select publications

Featuring an interview with Dr Heather Wakelee, including the following topics: Similarities and differences in the efficacy of neoadjuvant and adjuvant immunotherapies for localized non-small cell lung cancer (NSCLC) (0:00) Available data on the treatment of patients whose disease relapses on or after adjuvant immunotherapy (6:15) Activity of immunotherapy in patients whose tumors are EGFR mutated (10:29) Case: A woman in her mid 70s with EGFR-mutated NSCLC in her right lung (14:49) Case: A woman in her early 60s with a smoking history and a 4-cm right lower lobe lesion (24:17) Case: A man in his mid 50s with a smoking history and a left upper lobe mass with high PD-L1 expression (28:04) Optimal treatment of localized NSCLC in patients who have alterations in RET, BRAF and ALK (33:08) Importance of primary care doctors screening their patients for lung cancer (37:03) CME information and select publications

Featuring a slide presentation and related discussion from Dr Heather Wakelee, including the following topics: Key efficacy and safety data with belantamab mafodotin for multiple myeloma (MM) (0:00) Guidelines for the prevention and management of keratopathy in patients receiving belantamab mafodotin (3:46) Belantamab mafodotin in combination with pomalidomide; recent data and ongoing trials with BCMA-targeted bispecific antibodies (7:30) BCMA-targeted CAR (chimeric antigen receptor) T-cell therapies under evaluation for MM (17:07) CME information and select publications

Featuring perspectives from Dr Richard Penson, including the following topics: Introduction: Journal Club with Richard T Penson, MD, MRCP (0:00) Case: A woman in her mid 70s with Stage IIIB BRCA wild-type, high-grade serous ovarian cancer (HGSOC) who receives neoadjuvant and adjuvant carboplatin/paclitaxel and develops severe thrombocytopenia on maintenance niraparib — Gigi Chen, MD (12:28) Case: A woman in her late 30s with Stage IIC BRCA wild-type HGSOC who undergoes surgery and receives carboplatin/paclitaxel (LOH-negative) — Dana M Chase, MD (24:39) Case: A woman in her early 60s with Stage IIIC HGSOC and a germline BRCA1 mutation who receives IV/IP paclitaxel/cisplatin — Paul DiSilvestro, MD (28:11) Case: A woman in her early 60s with BRCA wild-type, HRD-negative peritoneal cancer who received neoadjuvant and adjuvant carboplatin/paclitaxel and now presents with altered mental status and a cerebellar metastasis — Karim ElSahwi, MD (34:40) Faculty Survey (40:37) Case: A woman in her early 70s with multiregimen-recurrent endometrioid ovarian adenocarcinoma with a germline PALB2 mutation develops breast cancer during maintenance niraparib — Dr Chase (50:02) Case: A woman in her late 60s with Stage IV BRCA wild-type, HRD-negative HGSOC develops anemia on maintenance olaparib/bevacizumab — Priya Rudolph, MD (59:25) CME information and select publications

Featuring perspectives from Dr Mark Pegram, including the following topics: Introduction: Journal Club with Dr Pegram (0:00) Case: A woman in her mid 60s with ER/PR-negative, HER2-positive metastatic breast cancer after multiple lines of HER2-directed therapy with no evidence of disease after 8 years of pertuzumab/trastuzumab — Raman Sood, MD (22:35) Case: A woman in her early 60s with a 1.8-cm triple-positive invasive ductal carcinoma after partial mastectomy/axillary lymph node dissection (9 N+) receives adjuvant TCHP x 6 — Shaachi Gupta, MD, MPH (27:30) Case: A woman in her early 70s with de novo ER-positive, HER2-positive breast cancer develops asymptomatic, bilateral brain metastases on TCHP — Chris Prakash, MD (36:02) Case: A woman in her early 30s with ER/PR-positive, HER2-negative breast cancer after neoadjuvant dose-dense doxorubicin and cyclophosphamide -> paclitaxel and bilateral mastectomy, now with HER2-positive disease on repeat testing — Zanetta S Lamar, MD (46:08) Case: A woman in her mid 40s with triple-negative breast cancer at biopsy declines neoadjuvant therapy and at surgery has a 3.2-cm node-negative, HER2-positive tumor — Alan B Astrow, MD (53:20) CME information and select publications

Featuring perspectives from Dr Lecia Sequist, including the following topics: Introduction: Journal Club with Lecia V Sequist, MD, MPH (0:00) Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an EGFR exon 19 mutation— Adam R Miller, MD (19:26) Case: A man in his late 70s with metastatic adenocarcinoma of the lung and an EGFR L858R mutation develops hemoptysis from an "escape lesion" on osimertinib — Priya Rudolph, MD, PhD (24:59) Case: A man in his early 70s with metastatic adenocarcinoma of the lung (PD-L1 high) and an EGFR L858R mutation experiences disease progression on pembrolizumab — Sandip Patel, MD (28:45) Case: A woman in her mid 60s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion with multiple brain and bone metastases (PD-L1 Case: A woman in her mid 50s with metastatic adenocarcinoma of the lung and an EGFR mutation experiences disease progression after response to osimertinib x 3 years (PD-L1 TPS 80%) — Gigi Chen, MD (43:44) Case: A man in his mid 50s with adenocarcinoma of the lung and an EGFR exon 19 mutation with brain metastases and disease progression on both osimertinib and carboplatin/paclitaxel/pembrolizumab/bevacizumab (ROS fusion detected on RNA assay) — Namrata I Peswani, MD (59:12) CME information and select publications

Featuring a slide presentation and related discussion from Dr Stephen Ansell, including the following topics: Recent updates in the first-line management of advanced classical Hodgkin lymphoma (0:00) Emerging data with immune checkpoint inhibitors when combined with current treatment strategies (4:40) Current and future management of early-stage disease (9:53) Treatment options for patients with relapsed HL (17:52) Later-line options for patients with multiply-relapsed disease (24:46) CME information and select publications

Featuring perspectives from Dr Stephen Ansell, including the following topics: Evolution of first-line management of advanced Hodgkin lymphoma (HL) (0:00) Transplant strategies and outcomes for patients with relapsed/refractory HL (4:20) Chemoimmunotherapy options for patients with HL (8:06) Current and future management of limited-stage disease (11:52) Addition of antibody-drug conjugates to HL treatment strategies (22:52) Long-term management of HL (29:16) Future management of HL — novel agents and strategies (34:56) CME information and select publications

Featuring a slide presentation and related discussion from Dr Charles Powell, including the following topics: Pathophysiology and clinical features of interstitial lung disease (ILD) associated with anticancer therapies (0:00) Anticancer therapies linked to the development of ILD (5:28) Patterns of ILD presentation and optimal evaluation of suspected ILD; treatment guidelines based on grade of severity (12:21) ILD associated with antibody-drug conjugates (21:06) Answers to common questions about the diagnosis and management of ILD in cancer patients (38:33) Representative cases of ILD associated with anticancer drugs (43:21) CME information and select publications